Scholarlink

Purpose <p>In somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [<sup>18</sup>F]SiTATE in pheochromocytoma and paraganglioma (PPGL) patients, focusing on eligibility for peptide radioreceptor therapy (PRRT) and therapy monitoring.</p> Methods <p>Five patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [<sup>18</sup>F]SiTATE applying the Krenning score and baseline SUV<sub>max</sub>. Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA).</p> Results <p>At baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUV<sub>max</sub> 41.4 ± 87.3) and a high Krenning Score of 3–4, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response.</p> Conclusion <p>In metastatic PPGL, [<sup>18</sup>F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[18F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月19日

查看全文
  • Sophie C. Siegmund,
  • Adrien Holzgreve,
  • Magdalena Schöll,
  • Vera U. Wenter,
  • Gabriel T. Sheikh,
  • Maximilian Scheifele,
  • Franz Josef Gildehaus,
  • Simon Lindner,
  • Matthias K. Auer,
  • Christian Lottspeich,
  • Matthias Kroiß,
  • Svenja Nölting,
  • Friederike Völter,
  • Christine Spitzweg,
  • Christoph J. Auernhammer,
  • Rudolf A. Werner,
  • Mathias J. Zacherl

摘要

Purpose

In somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [18F]SiTATE in pheochromocytoma and paraganglioma (PPGL) patients, focusing on eligibility for peptide radioreceptor therapy (PRRT) and therapy monitoring.

Methods

Five patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [18F]SiTATE applying the Krenning score and baseline SUVmax. Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA).

Results

At baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUVmax 41.4 ± 87.3) and a high Krenning Score of 3–4, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response.

Conclusion

In metastatic PPGL, [18F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.